Lynx1 Capital Management LP 13D and 13G filings for C4 Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 09:01 am Purchase |
2024-09-30 | 13G | C4 Therapeutics, Inc. CCCC |
Lynx1 Capital Management LP | 6,880,527 9.900% |
3,746,131 (+119.52%) |
Filing |
| 2024-02-14 09:21 am Purchase |
2023-12-31 | 13G | C4 Therapeutics, Inc. CCCC |
Lynx1 Capital Management LP | 3,134,396 6.400% |
12,177 (+0.39%) |
Filing |
| 2023-11-13 4:55 pm Purchase |
2023-11-01 | 13G | C4 Therapeutics, Inc. CCCC |
Lynx1 Capital Management LP | 3,122,219 6.300% |
3,122,219 (New Position) |
Filing |